Cue Biopharma (CUE) Competitors

Acrivon Therapeutics (NASDAQ:ACRV) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.

Do analysts recommend ACRV or CUE?

Acrivon Therapeutics currently has a consensus target price of $23.67, suggesting a potential upside of 264.66%. Cue Biopharma has a consensus target price of $5.00, suggesting a potential upside of 380.63%. Given Cue Biopharma's higher probable upside, analysts plainly believe Cue Biopharma is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cue Biopharma	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in ACRV or CUE?

Cue Biopharma received 113 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 97.06% of users gave Acrivon Therapeutics an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote.

Company	Underperform	Outperform
Acrivon Therapeutics	Outperform Votes 33 97.06%	Underperform Votes 1 2.94%
Cue Biopharma	Outperform Votes 146 52.33%	Underperform Votes 133 47.67%

Which has more risk & volatility, ACRV or CUE?

Acrivon Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Which has higher valuation and earnings, ACRV or CUE?

Cue Biopharma has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$60.39M	-$2.70	-2.40
Cue Biopharma	$5.49M	9.22	-$50.73M	-$0.90	-1.16

Do institutionals & insiders have more ownership in ACRV or CUE?

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 12.3% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media prefer ACRV or CUE?

In the previous week, Acrivon Therapeutics had 6 more articles in the media than Cue Biopharma. MarketBeat recorded 15 mentions for Acrivon Therapeutics and 9 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.27 beat Acrivon Therapeutics' score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Is ACRV or CUE more profitable?

Acrivon Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -468.02%. Acrivon Therapeutics' return on equity of -47.95% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-47.95%	-43.73%
Cue Biopharma	-468.02%	-156.38%	-88.07%

Summary

Cue Biopharma beats Acrivon Therapeutics on 9 of the 16 factors compared between the two stocks.